跳转至内容
Merck
CN

890810P

Avanti

18:0 DDAB

Avanti Research - A Croda Brand

别名:

双十八烷基二甲基铵(溴化盐)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C38H80NBr
CAS号:
分子量:
630.95
UNSPSC代码:
12352211
NACRES:
NA.25

形式

powder

包装

pkg of 1 × 1 g (890810P-1g)
pkg of 1 × 200 mg (890810P-200mg)
pkg of 1 × 25 mg (890810P-25mg)
pkg of 1 × 500 mg (890810P-500mg)

制造商/商品名称

Avanti Research - A Croda Brand

应用

vaccine development

脂质类型

cationic lipids
transfection

运输

dry ice

储存温度

−20°C

SMILES字符串

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1

InChI key

PSLWZOIUBRXAQW-UHFFFAOYSA-M

一般描述

18:0 DDAB是阳离子脂质和季铵盐。与可电离的脂质不同,烃尾巴是饱和的。

应用

18:0 DDAB适合制备脂质纳米颗粒。它还可用作佐剂,与单磷酸脂A(MPL)联合用于免疫小鼠。

生化/生理作用

18:0 DDAB是一种表面活性分子,可用作诱导全身免疫反应的佐剂。无毒。

包装

20 mL透明玻璃螺旋盖样品瓶(890810P-1g)
20 mL透明玻璃螺旋盖样品瓶(890810P-500mg)
5 mL棕色玻璃螺旋盖样品瓶(890810P-200mg)
5 mL棕色玻璃螺旋盖样品瓶(890810P-25mg)

其他说明

仅供研发使用。& 不可用于药物、家庭或其他用途。

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

通常也和此产品一起购买

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens
Klinguer C, et al.
Vaccine, 19(30), 4236-4244 (2001)
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel S, et al.
J. Controlled Release, 303, 91-100 (2019)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门